Data / Form D filings / VentiRx Pharmaceuticals Inc.
VentiRx Pharmaceuticals Inc.: Form D filings
VentiRx Pharmaceuticals Inc., a biotechnology company in Seattle, WA, filed 4 Form D notices with the SEC between 2010 and 2014. The latest, on September 30, 2014, reports $15 million sold of a $15 million offering to 1 investor.
Find out what VentiRx Pharmaceuticals Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1191 SECOND AVE., SUITE 1105, Seattle, WA, 98101
- Phone
- (206) 689-2259
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1367762
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2014 | New notice | $15,000,000 | $15,000,000 | $0 | 1 | Sep 22, 2014 | sec.gov |
| Sep 23, 2014 | Amendment | $53,102,414 | $50,602,514 | $2,499,900 | 9 | Jan 8, 2010 | sec.gov |
| Mar 8, 2012 | Amendment | $25,000,002 | $18,750,001 | $6,250,001 | 5 | Jan 8, 2010 | sec.gov |
| Jan 22, 2010 | New notice | $25,000,002 | $12,500,001 | $12,500,001 | 5 | Jan 8, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ron M. Laufer | Director | |
| Atul M. Saran | Director | |
| Kathleen M. Fanning | Executive Officer | |
| Robert M. Hershberg, M.D., Ph.D. | Executive Officer, Director | |
| Kent M. Snyder | Director | |
| Steven M. Gillis, Ph.D. | Director | |
| Patrick M. Heron | Director | |
| Nicole M. Vitullo | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Sep 29, 2014 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what VentiRx Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.